Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
For Orph Pharma Limited. Looks like sorting shares for distribution to existing Orph holders
https://find-and-update.company-information.service.gov.uk/company/13279507/filing-history
Don't think he's interested in supporting the SP like that if he plans to buy after results. Last night he seemed to be saying sorry but news will be quiet until after results
Fair enough, I was meaning as in it's the single cell organism infecting mosquitos, Plasmodium, that's the issue, not the parasitic mosquito itself.
The AGS-v approach of targeting mosquito saliva protein is interesting. It's supposed to stimulate a quick immune response to nip infection in the bud early. But have they proven it prevents infection with malaria or Zika yet or just that it illicits a significant immune response to further saliva exposure which might prevent infection?
Malaria caused by Plasmodium bacteria in mosquito https://en.m.wikipedia.org/wiki/Plasmodium
If SGS is the buyer of open Orphan, I think they'd want to keep the data business, it could fit in well with their full service offer to big pharma. The wearables data Idea is possibly not the big story with this data either. If you look through old company reports on Pathomics for drug development, this could be the real value for the data and very valuable to SGS.
The talking up of a data spin-out might be a useful leaver to bump up the offer price from SGS.
In the presentation, I thought he specifically talked about a deal to continue getting data from Open Orphan once the data company is spun-out
I've emailed IR again with questions about the first spin-out and subsequent spin-outs to see if this bigger slice of the pie for CF will be a theme across the next 3. It's even less justified for the likes of Imutex and Prep Biopharm where he will be less hands on. I'll post the response.
Seek are trying to maximise the value of the peptide vaccine platform they are putting into ConserV Biosciences. The mosquito and flu vacc are just part of that. They are also developing a universal coronavirus vacc which they have a partner and funding for early stage development.
This is why some of the reasons it's slow progress...
I'll leave you all here to carry on this discussion and scrutiny of the spin-offs. I only wanted to get debate going so this board is not just a fan club.
Since the Poolbeg articles of association came out I suggested that CF was going to end up with more % of the first spin-off than his Open Orphan shares should give him. I was shouted down by people who claimed to be more in the know or more experienced. As the picture became more clear proving me right their disagreement became louder. Now this is proven fact they are louder still, with some like Greend100 still misunderstanding the figures and facts.
Some are fine with the very generous deal Cathal is awarding himself, a deal I've not voted for and that is not in the remuneration report for the company. Others who are not ok with this should be free to give their views with out the playground style personal attacks.
Let's keep this health debate going and a skeptical eye on the company. Scrutiny is for the benefit of all shareholders.
That sounds much more reasonable and accountable and transparent. You should suggest that the the board. Better than the current setup. Chances are they will also get some sort of share incentive scheme on top of their free shares and possibly salary too
Well researched there Barwickman, Neil Woodford, famous ex CEO of hVivo, not an institutional investor/ fund manager.
There is no doubt hVivo was badly managed. But it doesn't justify getting caught with your hand in the cookie jar
Keep a close eye on the details for the other spin-outs. I've 100% confidence that CF is trying to maximise shareholder value from the non-core assets, but as a long term holder I'm not happy with him taking extra slices of the pie along the way
I've held hVivo since 2018. CF got hVivo for a bargain price, and has done very well with its assets. I'm banging on about long term holders getting their fair share of assets.
Unless he has put in some seed funding (which seems unlikely given planned fundraising), getting potentially 3% of Poolbeg (before dilution from fundraising) seems a tad too generous in my opinion. Assuming they make a success of Poolbeg, this could be worth 10s of millions, what will have justified this?
Holding, have been since 2018. My exit is SGS buying Orph
Looks like news will continue to be managed/held back until after results, that's when CF said he would be buying more shares, I wonder how many contracts will be announced after CF buys...
They have all the C19 CHIM slot's to announce as the characterisation study will be finished and real CHIMs can start.
I always find that such a strange response. "If you are not happy with a feature of the company you are invested in sell". This is just one aspect of open Orphan. The company as a whole is still a solid prospect and I expect to make 3x minimum from here (not including spin-outs). Everyone is so sensitive to talking about anything that is not positive.
Why doesn't anyone respond instead of the personal attacks.
Do you think it is fair that CF will own possibly 50% more Poolbeg Pharma Limited shares than he should get based only on his Open Orphan shares?
Sparkington, check companies House for details of the new team and their holdings in Poolbeg
CF said in his presentation that Open Orphan shareholders will get over 90% of the Poolbeg Pharma shares before dilution. Currently Poolbeg Pharma is owned by 5 people with CF owning two thirds. After the assets move, those 5 people will own less than 10%. however, CF owns 6.69% of Open Orphan shares so he will get 6.69 % of this 90% plus. And he will still own 66% of the less than 10%.
It is a bit complicated but CF just justified it as providing a little incentive for the management team in his presentation. A very generous incentive if you ask me
Sorry, wrong website, I thought this was for investors discussion not the Cathal Friel fan club. My mistake DDB
My agenda is to get my full share of the assets I've been invested in since 2018 in hVivo. Why should CF increase his share of these assets by nearly 50%